Bioequivalence

 If two medicines are bioequivalent there is no clinically significant difference in their bioavailability. Although bioequivalence is most commonly discussed in relation to generic medicines, it is important to note that bioequivalence studies are also performed for innovator medicines in some situations such as: between early and late clinical trial formulations or between the formulations used in clinical trials and the product to be marketed for new medicines when changes in formulation have occurred after an innovator product has been approved, for example a change in one or more excipients (inactive ingredients).

 

  • Pharmacokinetic Studies
  • Pharmacodynamic Studies
  • Clinical Studies
  • IVIVC
  • Earlier exposure on BE

Related Conference of Bioequivalence

March 23-24, 2020

World Congress on Biosensors and Bioelectronics

Osaka, Japan
April 16-17, 2020

16th World Congress on Structural Biology

Amsterdam, Netherlands
April 20-21, 2020

11th Tissue Science and Regeneration Congress

Kualalumpur, Malaysia
June 28-30 2020

globalbiotechnology-cs-2020

June 28-30 2020

oilgas-cs-2020

June 28-30 2020

BEHAVIOURAL SCIENCE-2020

June 28-30 2020

Bioinfo 2020

May 10-11, 2020

26th World Nursing & Nurse Practitioner Conference

Yokohama, Japan
July 17-18, 2020

10th Glycobiology World Congress

Vienna, Austria
August 4-5, 2020

12th Euro Biosensors & Bioelectronics Congress

Zurich, Switzerland
September 28-29, 2020

2nd International Conference on Metabolomics, Genomics and Proteomics

Singapore City, Singapore
September 28-29, 2020

19th International Conference on Structural Biology

Barcelona, Spain
October 08-09, 2020

10th European Biosimilars Summit

Milan, Italy
October 14-15, 2020

9th World Congress on Glycobiology & Glycochemistry

Rome, Italy

Bioequivalence Conference Speakers

Recommended Sessions

Related Journals

Are you interested in